-
DiscoveryProbe FDA-approved Drug Library: SKU L1021
2026-09-04
Learn how DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) can support reproducible cell-viability, proliferation, cytotoxicity, and drug repositioning screening workflows. This scenario-driven guide connects assay controls, protocol design, data interpretation, and practical library-selection criteria with published high-throughput screening evidence.
-
IWP-L6: A Causal Probe of Wnt Metabolism
2026-09-03
Discover how IWP-L6, a potent Porcupine inhibitor, can separate upstream Wnt ligand maturation from downstream metabolic responses. This article translates recent O-GlcNAcylation findings into a rigorous assay strategy for interpreting Wnt-dependent osteogenesis, regeneration, and tissue patterning experiments.
-
Fenipentol Workflows for Secretion Research
2026-09-03
Fenipentol, also called 1-Phenyl-1-pentanol, connects natural-product profiling with practical studies of hepatobiliary and pancreatic secretion. This guide shows how to build concentration-response assays, compare Ligusticum chuanxiong tissue chemistry, and troubleshoot solubility, vehicle, and matrix effects.
-
Self-Amplifying RNA Vaccines for Influenza: Study Analysis
2026-09-02
This reference study shows that self-amplifying RNA can overcome the weak influenza B responses reported for conventional mRNA vaccine designs while reducing the antigen dose required in mice. Its systematic comparison of modified mRNA, self-amplifying RNA, and circular RNA highlights platform- and subtype-specific determinants of immunogenicity, durability, and protection.
-
Bufalin–CRISPR Nanomedicine for Colorectal Cancer
2026-09-02
This 2025 Materials Today Bio study reports CLBRP, a calcium lactate nanomedicine that co-delivers bufalin and a CD47-targeting CRISPR/Cas9 ribonucleoprotein to coordinate tumor-cell death with immune remodeling. Its significance lies in combining pyroptosis, apoptosis, macrophage M1 repolarization, and removal of CD47-mediated antiphagocytic signaling within one treatment strategy.
-
LMO2–LDB1 Signaling in Acute Myeloid Leukemia
2026-09-01
The reference study identifies an LMO2/LDB1 protein complex as a functional driver of acute myeloid leukemia, moving beyond LMO2 expression correlations to test mechanistic dependency. Its combined perturbation, interaction, transcriptomic, chromatin, and in vivo evidence supports LDB1 as an important regulator of AML-cell proliferation and survival while clarifying the partial contribution of LMO2.
-
ERH Knockdown Restrains Ovarian Cancer Progression
2026-09-01
The reference study links elevated enhancer of rudimentary homolog (ERH) expression with adverse clinicopathological features and poor ovarian cancer prognosis. Using shRNA knockdown in SKOV3 cells, the authors further show that ERH depletion suppresses proliferation, invasion, metastasis-related behavior, and epithelial–mesenchymal transition while promoting apoptosis.
-
IR-1061: State-Aware NIR-II Imaging
2026-08-31
IR-1061 is a near infrared fluorescent dye whose performance depends on solvent, aggregation state, and biological formulation. This guide translates mechanistic findings into practical assay decisions for in vivo imaging, optical imaging, and biomedical research.
-
BPN-19186 Workflow for sEH–Nrf2 Research
2026-08-31
BPN-19186 supports a tiered workflow that connects soluble epoxide hydrolase activity with lipid-epoxide metabolism, Nrf2 signaling, and osteoclast differentiation. Its organic-solvent solubility and research-grade characterization make it practical for biochemical screening followed by cell-based mechanism testing.
-
Diuron-Induced Acute Kidney Injury: JAK2/STAT1
2026-08-30
The reference study integrates network toxicology, transcriptomic validation, molecular docking, and HK-2 cell experiments to investigate how Diuron may promote acute kidney injury. Its central finding is that JAK2/STAT1 signaling is associated with Diuron-induced renal cellular injury, providing a mechanistic framework for environmental toxicology and future causality studies.
-
Disodium Bicinchoninate in Cardiac Cell Assays
2026-08-29
Disodium bicinchoninate enables water-based protein normalization and assay development for high-glucose cardiomyocyte, fibroblast, and BMSC workflows. This guide translates the cGMP/PKG findings of a cardiac fibrosis study into practical reagent preparation, matrix controls, and troubleshooting strategies.
-
Midecamycin Workflows for Resistance Research
2026-08-28
Midecamycin combines ribosomal target validation with practical resistance and glycosylation workflows. This guide shows how to use the compound as a bacterial protein synthesis inhibitor, benchmark Gram-positive activity, and investigate sugar-mediated inactivation without confusing research findings with clinical breakpoints.
-
DiscoveryProbe FDA-approved Drug Library for HTS
2026-08-28
The DiscoveryProbe FDA-approved Drug Library connects clinically familiar chemistry with mechanism-guided cancer screening, enabling researchers to move from a 14-3-3ζ binding assay to cellular validation and target engagement. Its pre-dissolved 10 mM DMSO format supports reproducible drug repositioning screening without the preparation burden of assembling thousands of individual compounds.
-
HyperScript RT SuperMix for qPCR: CRC Biomarkers
2026-08-27
HyperScript RT SuperMix for qPCR provides a technically grounded route from challenging RNA to reproducible cDNA synthesis for qPCR. This article applies its enzyme and primer design to the practical validation of colorectal cancer biomarkers identified through integrated transcriptomics and survival modeling.
-
WP1066: A Causal Tool for JAK2/STAT3 Biology
2026-08-27
WP1066 is a cell-permeable JAK2/STAT3 inhibitor for connecting pathway inhibition with cancer-cell phenotypes and macrophage immunometabolism. This article focuses on causal assay design, translational boundaries, and how the infectious bone-regeneration literature informs—not overstates—its use.